缺非碳氧化矩阵格拉蛋白与心力衰竭的不良结果有关
Mahesh K Vidula1,2, Leon J Schurgers3, Lei Zhao4
1Division of Cardiovascular Medicine, Hospital of the University of Pennsylvania, Philadelphia (M.K.V., M.-J.D., M.Z., P.Z., T.P.C., J.A.C.).
Circulation. Heart failure
|January 28, 2026
概括
不活性矩阵格拉蛋白 (dpucMGP) 与心力衰竭 (HF) 患者的结果更差有关. 较高的dpucMGP水平增加了死亡或住院的风险,并调解了华法林.
科学领域:
- 心血管医学 心血管医学
- 蛋白质组学是指蛋白质组学.
- 生物化学 生物化学
背景情况:
- 矩阵格拉蛋白 (MGP) 对于防止血管化至关重要,需要维生素K依赖的碳活化来激活.
- 过高的非活性MGP (dpucMGP) 与动脉硬化和心力衰竭 (HF) 中肌肉质量减少相关.
- 在HF患者中dpucMGP的预后意义仍然不清楚.
研究的目的:
- 研究dpucMGP血水平与大量高风患者的不良临床结果之间的关联.
- 探索dpucMGP的蛋白质组联系,并确定相关的生物通路.
- 确定dpucMGP水平是否调解了华法林使用和高频率的不良结果之间的关系.
主要方法:
- 血dpucMGP在宾夕法尼亚大学HF研究 (PHFS) 的2247名参与者中进行了测量.
- 蛋白质组分析 (SomaScan测定) 确定了与dpucMGP.相关的约5000种蛋白质.
- 评估了dpucMGP与死亡或HF相关住院的风险,以及所有原因死亡之间的关联.
主要成果:
- 较高的dpucMGP水平与死亡或与HF相关的住院风险增加显著相关 (SHR 1.23) 和全因死亡 (SHR 1.32).
- dpucMGP显示了蛋白质组与急性阶段反应,凝血,补充,纤维化,细胞信号和代谢途径的联系.
- 较高的dpucMGP调解了华法林使用和不良结果之间的关联,特别是在非胰岛素HF.
结论:
- 升高的dpucMGP是HF患者不良结果的重要预测因素.
- dpucMGP涉及各种生物途径,并调解华法林的不良影响.
- 需要进一步的研究来探索针对dpucMGP减少HF的治疗策略.
相关概念视频
01:29Heart Failure II: Pathophysiology
872
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
872
01:17Pathophysiology of Heart Failure
3.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.5K
01:27Heart Failure I: Introduction
847
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
847
01:22Heart Failure VI: Adjunct Therapies
314
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
314
01:22Heart Failure Drugs: Diuretics
948
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
948
01:30Heart Failure V: Medical Management
272
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
272